SpyGlass Pharma, Inc. SGP
Regular-session close
After hours · Nov 20, 4:01 PM ET
- YTD
- +15.27%
- 1 year
- +15.27%
5D -1.14 (-3.51%)
- Market cap
- 1.02B
- EPS (ttm)
- -2.70
- Shares out
- 33.46M
- Forward P/E
- -10.04
- YTD return
- +15.27%
- 1-year return
- +15.27%
- 50-day average
- 29.01
- 200-day average
- 25.02
- Enterprise value
- 815.79M
- Volume
- 108.91K
- Avg volume
- 113.74K
- Open
- 30.12
- Previous close
- 30.78
- Day's range
- 29.60 – 31.73
- 52-week range
- 17.56 – 38.37
- Analysts
- Strong Buy
- Price target
- 46.67 (+53.4%)
- Earnings date
- Mar 25, 2027
Key statistics
- Price / book
- 4.84
- Free cash flow
- -37.95M
- Total cash
- 215.76M
- Total debt
- 1.61M
- Return on equity
- -43.01%
- Short % of float
- 10.44%
Fundamental scorecard
4 of 25 checks passed on SGP’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 42.00
- Target (mean)
- 46.67
- Target (high)
- 62.00
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 25, 2027
Expected Mar 25, 2027. Consensus EPS estimate -0.62247.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 25, 2027 | Dec 30, 2026 | -0.77 | — | — | — |
| Nov 11, 2026 | Sep 30, 2026 | -0.62247 | -0.73 | -0.11 | -17.27% |
| Aug 6, 2026 | Jun 30, 2026 | -0.51442 | -0.59 | -0.08 | -14.69% |
| May 15, 2026 | Mar 31, 2026 | -0.67 | -0.69 | -0.02 | -2.99% |
| Mar 26, 2026 | Dec 31, 2025 | -0.57422 | -5.72 | -5.15 | -896.13% |
| Dec 3, 2025 | Sep 30, 2025 | — | -0.44776 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 13, 2026 | Citigroup | main | Buy | Buy |
| Nov 13, 2026 | Stifel | main | Buy | Buy |
| Nov 12, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 21, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 5, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2026 | Raymond James | init | — | Outperform |
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- spyglasspharma.com
News
Citigroup Maintains Buy on SpyGlass Pharma, Raises Price Target to $45
Stifel Maintains Buy on SpyGlass Pharma, Raises Price Target to $44
HC Wainwright & Co. Maintains Buy on SpyGlass Pharma, Raises Price Target to $43
SpyGlass Pharma Q3 EPS $(0.73) Misses $(0.63) Estimate
HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target
Your note
Sign in to keep a note on SGP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASKETT FOREST | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 8, 2026 | 0 |
| BEHBAHANI ALI | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 8, 2026 | 0 |
| CHANG CARMEN | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 8, 2026 | 0 |
| FLORENCE ANTHONY A JR | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 8, 2026 | 0 |
| MAKHZOUMI MOHAMAD | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 8, 2026 | 0 |
| MATHERS EDWARD T. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 8, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 23.97% | 8,021,117 | 244.08M | Sep 29, 2026 |
| NEA Management Company, LLC | 22.09% | 7,392,301 | 224.95M | Sep 29, 2026 |
| Sands Capital Alternatives, LLC | 7.47% | 2,500,012 | 76.08M | Sep 29, 2026 |
| Samsara BioCapital, LLC | 6.31% | 2,109,953 | 64.21M | Sep 29, 2026 |
| JPMORGAN CHASE & CO | 3.00% | 1,003,268 | 30.53M | Sep 29, 2026 |
| Price (T.Rowe) Associates Inc | 2.77% | 925,767 | 28.17M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 0.95% | 317,053 | 9.65M | Jun 29, 2026 |
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 0.87% | 291,272 | 8.86M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.74% | 247,196 | 7.52M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.73% | 245,044 | 7.46M | Sep 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 0.69% | 229,706 | 6.99M | Jun 29, 2026 |
| abrdn Healthcare Investors | 0.64% | 214,473 | 6.53M | Jun 29, 2026 |
